Bhavana Pothuri, Sileny Han, Dana M Chase, Florian Heitz, Robert A Burger, Lydia Gaba, Linda Van Le, Eva Guerra, David Bender, Jacob Korach, Noelle Cloven, Cristina Churruca, Philippe Follana, Paul DiSilvestro, Jean-François Baurain, Kris Jardon, Carmela Pisano, Ulla Peen, Johanna Mäenpää, Divya Gupta, Emeline Bacqué, Yong Li, Natalie Compton, Jenya Antonova, Bradley J Monk, Antonio González-Martín
OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. METHODS: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) to niraparib or placebo once daily in 28-day cycles until disease progression, intolerable toxicity, or death...
February 6, 2024: Gynecologic Oncology